EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NIBAN2/FLII/RREB1 Axis Drives Glioma Stem Cell Malignancy via TLR3 Pathway Activation

Liang Liang Shi, Xinwei Qiao, Yue Hu, Minjie Wang, Shaojie Yu, Zihan Gong, Yuxin Rao, Hui Zheng, Siting Chen, Lin Li, Rong Fu, Tao Liang und 3 weitere

Advanced Science · 2026-05 · 13 (26)

DOI: 10.1002/advs.202519382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 25.02.2026. Verfasst von Liang Liang Shi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Glioma, DNA-Binding Proteins, Toll-Like Receptor 3. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Laboratory of Molecular Biological Targeted Therapies of the Ministry of Education (Huazhong University of Science and Technology), Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioma stem‐like cells (GSCs), characterized by self‐renewal capacity, therapeutic resistance, and high tumorigenicity, are considered the fundamental drivers of glioma aggressiveness and recurrence. However, the core regulatory mechanisms underlying GSCs stemness maintenance remain unclear. In this study, we identified that the NIBAN2 is highly expressed in glioma tissues and GSCs, and its expression is closely associated with poor patient prognosis. Functional experiments demonstrated that NIBAN2 directly binds to Flightless I (FLII) and enhances its interaction with the transcription factor Ras‐responsive element‐binding protein 1 (RREB1), thereby promoting nuclear translocation. Together, the NIBAN2‐FLII‐RREB1 complex activates the Toll‐like receptor (TLR3) signaling pathway, sustaining the stem‐like phenotype and tumorigenic potential of GSCs. Further investigation revealed that RREB1 transcriptionally upregulates NIBAN2 and CD44, promoting the expression of the key glycolytic enzyme LDHA (Lactate Dehydrogenase A). This establishes a feed‐forward signaling‐transcription‐metabolism axis driven by NIBAN2/FLII/RREB1, facilitating metabolic reprogramming. Multi‐omics and metabolomic analyses confirmed that this loop enhances glycolytic flux to maintain GSCs’ metabolic homeostasis. Drug screening identified the HIV protease inhibitor nelfinavir as a specific disruptor of the NIBAN2‐FLII complex. When combined with the LDHA inhibitor FX11, it induced synergistic anti‐tumor effects in organoid and patient‐derived xenograft models, thereby significantly inhibiting tumor progression and prolonging survival. Clinical samples further confirmed the co‐upregulation of NIBAN2, FLII, and RREB1 in GBM (Glioblastoma) tissues, which correlates with SOX2 and Ki‐67 expression and poor prognosis. Collectively, this study, for the first time, reveals that NIBAN2 maintains GSCs stemness by activating FLII‐RREB1 axis and TLR3 signaling, thereby establishing a feed‐forward signaling‐transcription‐metabolism axis. This finding provides a novel strategy and potential targets for precise therapeutic intervention against glioma stemness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Stem CellsGliomaDNA-Binding ProteinsToll-Like Receptor 3Transcription FactorsBrain NeoplasmsHumansAnimalsSignal TransductionMiceCell Line, Tumor

Stichwörter der Autor:innen

NIBAN2/FLII/RREB1TLR pathwayglioma stem cellsmetabolic reprogramming

Substanzen

DNA-Binding ProteinsToll-Like Receptor 3Transcription FactorsTLR3 protein, human

Autor:innen und Institutionen

  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Emergency, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

ORCID-Profile: Junjun Li

Förderung

  • Key Laboratory of Molecular Biological Targeted Therapies of the Ministry of Education (Huazhong University of Science and Technology)
  • Hubei Key Laboratory of Biological Targeted Therapy
  • Union Hospital
  • Tongji Medical College
  • Huazhong University of Science and Technology

Zitieren

APA

Shi, L. L., Qiao, X., Hu, Y., Wang, M., Yu, S., Gong, Z., Rao, Y., Zheng, H., Chen, S., Li, L., Fu, R., Liang, T., Yao, J., Jiang, X., & Li, J. (2026). NIBAN2/FLII/RREB1 Axis Drives Glioma Stem Cell Malignancy via TLR3 Pathway Activation. Advanced Science, 13(26). https://doi.org/10.1002/advs.202519382

Vancouver

Shi LL, Qiao X, Hu Y, Wang M, Yu S, Gong Z, et al. NIBAN2/FLII/RREB1 Axis Drives Glioma Stem Cell Malignancy via TLR3 Pathway Activation. Advanced Science. 2026;13(26). doi:10.1002/advs.202519382

BibTeX
@article{Shi2026,
  author = {Shi, Liang Liang and Qiao, Xinwei and Hu, Yue and Wang, Minjie and Yu, Shaojie and Gong, Zihan and Rao, Yuxin and Zheng, Hui and Chen, Siting and Li, Lin and Fu, Rong and Liang, Tao and Yao, Jin and Jiang, Xiaobing and Li, Junjun},
  title = {NIBAN2/FLII/RREB1 Axis Drives Glioma Stem Cell Malignancy via TLR3 Pathway Activation},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {26},
  doi = {10.1002/advs.202519382}
}
Kostenlos starten →